ヒトインスリンに対する世界的な需要の増加は、主に糖尿病の有病率の増加によるものです。ライフスタイルの変化、肥満や高齢者人口の増加、医療施設の不足が、世界的に糖尿病患者数を増加させる要因となっています。この市場の成長を促進するその他の要因としては、政府の有利な政策や、インスリン ペンの革新などの技術的進歩があります。さらに、医薬品の研究と製造に関する研究開発投資の増加と糖尿病への意識の高まりも、市場の成長を後押ししています。
目次
Contents
1. Executive Summary
2. Global Human Insulin Market
2.1. Product Overview
2.2. Market Definition
2.3. Segmentation
2.4. Assumptions and Acronyms
3. Research Methodology
3.1. Research Objectives
3.2. Primary Research
3.3. Secondary Research
3.4. Forecast Model
3.5. Market Size Estimation
4. Average Pricing Analysis
5. Macro-Economic Indicators
6. Market Dynamics
6.1. Growth Drivers
6.2. Restraints
6.3. Opportunity
6.4. Trends
7. Correlation & Regression Analysis
7.1. Correlation Matrix
7.2. Regression Matrix
8. Recent Development, Policies & Regulatory Landscape
9. Risk Analysis
9.1. Demand Risk Analysis
9.2. Supply Risk Analysis
10. Global Human Insulin Market Analysis
10.1. Porters Five Forces
10.1.1. The threat of New Entrants
10.1.2. Bargaining Power of Suppliers
10.1.3. Threat of Substitutes
10.1.4. Rivalry
10.2. PEST Analysis
10.2.1. Political
10.2.2. Economic
10.2.3. Social
10.2.4. Technological
11. Global Human Insulin Market
11.1. Market Size & forecast, 2019A-2030F
11.1.1. By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
11.1.2. By Volume (Million Units) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
12. Global Human Insulin Market: Market Segmentation
12.1. By Regions
12.2. By Regions
12.2.1. North America:(U.S. and Canada)
12.2.1.1. By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
12.2.2. Latin America: (Brazil, Mexico, Argentina, Rest of Latin America)
12.2.2.1. By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
12.2.3. Europe: (Germany, UK, France, Italy, Spain, BENELUX, NORDIC, Hungary, Poland, Turkey, Russia, Rest of Europe)
12.2.3.1. By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
12.2.4. Asia-Pacific: (China, India, Japan, South Korea, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia Pacific)
12.2.4.1. By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
12.2.5. Middle East and Africa: (Israel, GCC, North Africa, South Africa, Rest of Middle East and Africa)
12.2.5.1. By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
12.3. By Product: Market Share (2020-2030F)
12.3.1. HI Drugs, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
12.3.2. HI Delivery Devices, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
12.4. By Application: Market Share (2020-2030F)
12.4.1. Type II Diabetes, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
12.4.2. Type I Diabetes, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
12.4.3. Gestational Diabetes & Prediabetes, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
13. Company Profile
13.1. B. Braun Melsungen AG.
13.1.1. Company Overview
13.1.2. Company Total Revenue (Financials)
13.1.3. Market Potential
13.1.4. Global Presence
13.1.5. Key Performance Indicators
13.1.6. SWOT Analysis
13.1.7. Product Launch
13.2. ALBIREO PHARMA, INC
13.3. BECTON, DICKINSON AND COMPANY
13.4. BIOCON LIMITED
13.5. Sanofi Aventis
13.6. WOCKHARDT LIMITED
13.7. JULPHAR
13.8. YPSOMED HOLDING AG
13.9. ELI LILLY AND COMPANY
13.10. NOVO Nordisk A/S
13.11. ADOCIA
13.12. Tonghua Dongbao Pharmaceutical Co., LTD
13.13. GSK
13.14. Gulf Pharmaceutical Industries
13.15. Medtronic PLC
13.16. Oramed Pharmaceuticals, Inc
13.17. SemBioSys Genetics
13.18. Pfizer, Inc.
13.19. Merck & Co., Inc.
13.20. Other Prominent Players
14. Consultant Recommendation
**The above-given segmentations and companies could be subjected to further modification based on in-depth feasibility studies conducted for the final deliverable.
